- 單次注射 NT 45000
- 半年療程 NT 120000(含3次眼內注射，最多3次視網膜輔助雷射)
- 單次注射 NT 35000
- 半年療程 NT 100000(含3次眼內注射，最多3次視網膜輔助雷射)
Information for Patients With Macular Edema Following CRVO
If you or a loved one has been diagnosed with Macular Edema following Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO) , you are not alone.
Each year, there are approximately 2,000 new cases of Central Retinal Vein Occlusion (CRVO) or Branch Retinal Vein Occlusion (BRVO) in Taiwan.
IMPORTANT PRESCRIBING INFORMATION FOR EYLEA® (aflibercept) INJECTION
EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with Macular Edema following CRVO or BRVO. The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).
IMPORTANT SAFETY INFORMATION FOR EYLEA® (aflibercept) INJECTION
The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
Serious side effects related to the injection procedure are rare but can occur including infection inside the eye, retinal detachment, cataract, increased pressure in the eye, and vitreous detachment.